RxDoctor Payments Data

Edward Fox, MD

Hematology & Oncology · Nashville, TNNPI 1679546121

Payments from drug & device makers

$2,710in general payments, 2019–2025

Across 43 payments — averaging $63.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$2K
  • Genentech USA, Inc.$229
  • Novartis$120
  • Exelixis Inc.$57
  • Gilead$40
  • AstraZeneca$38
  • plus $309 from 16 others
$2,531in research payments, 2019–2025

Across 6 payments — averaging $421.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • TG Therapeutics, Inc.$3K

What the payments were for

  • Food & beverage$72227%
  • Education$703%
  • Gifts$1,91871%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,710 in reported general payments places this provider in the 25th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$291,059
Medicare patients
452
Services billed
8,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib22$346,530
JakafiRuxolitinib Phosphate22$328,683
CabometyxCabozantinib S-Malate11$264,585
RevlimidLenalidomide16$217,690
MekinistTrametinib Dimethyl Sulfoxide12$190,599
TafinlarDabrafenib Mesylate12$175,550
PromactaEltrombopag Olamine13$170,575
BrukinsaZanubrutinib13$168,229
Abiraterone Acetate53$124,556
EliquisApixaban59$37,317
XareltoRivaroxaban28$31,092
Enoxaparin Sodium14$4,415
Anastrozole147$2,216
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$1,824
Gabapentin23$1,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMekinist, Tafinlar, Promacta$120$536,72537 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$14$346,53022 claims
Exelixis Inc.Cabometyx$57$264,58511 claims
Johnson & JohnsonXarelto$28$31,09228 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$11$17016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 251 hematology & oncology providers in Tennessee.

Other hematology & oncology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →